SAN DIEGO, Calif., March 11 /PRNewswire-FirstCall/ -- Volcano Corporation , a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today its participation in the Annual Scientific Sessions of the American College of Cardiology (ACC) Conference from March 14th to March 16th in Atlanta, GA.
“The Percutaneous Coronary Intervention (PCI) procedures that benefit from our technology are very complex, often involving multi-vessel disease, bifurcations, left mains, chronic total occlusions, intermediate lesions, or various combinations,” commented Joe Burnett, Executive Vice President at Volcano. “Our message, however, is quite simple. Angiography alone is not enough. Multiple large studies including FAME, PROSPECT and STLLR have demonstrated that reliance on the two-dimensional x-ray image can be misleading, negatively impact hospital costs and deliver sub-optimal results to patients. It is inspiring to see that the agenda at ACC this year, which includes more than 50 symposium presentations, case reviews, abstracts and poster presentations discussing precision-guided tools like FFR, IVUS and OCT. These innovative technologies can augment angiography and confirm a therapeutic strategy and result.”
Volcano will also introduce new products into its comprehensive suite of integrated lab systems, coronary and peripheral IVUS catheters, and physiology wires measuring both pressure and flow. The products on display at Volcano’s booth #232 will include:
“The recent FDA clearance of our Eagle Eye(R) Platinum IVUS catheter, the integration of our FFR technology with hemodynamic monitoring systems, and our latest s5i software upgrade demonstrate the ongoing innovation occurring among all aspects of the Volcano business,” continued Mr. Burnett. “We are pleased to introduce these new products to the attendees at ACC and continue our work with clinicians to drive education and awareness of the benefits of IVUS and FFR. Clinical studies have shown that angiography alone is not always enough. We believe the use of Volcano’s technology to deliver therapy guidance to confirm disease severity and stent placement can greatly improve patient and clinical outcomes. The healthcare economy can no longer afford to ignore tools that will enable clinicians to treat their patients right the first time.”
Volcano’s innovative portfolio of therapy guidance technologies will be featured in live case transmissions and available for demonstration at Booth #232. Volcano’s s5i family of imaging systems will be also be on display in other booths, including GE Healthcare, Siemens Healthcare, Toshiba America Medical Systems, and Abbott Vascular.
About Volcano Corporation
Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company’s intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use digital and rotational IVUS imaging catheters, and advanced functionality options, such as VH(R) IVUS tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters. Currently, more than 5,000 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. Volcano’s wholly-owned subsidiary, Axsun Technologies, develops and manufactures optical monitors, lasers and optical engines used in telecommunications, medical imaging, spectroscopy and other industrial applications. For more information, visit the company’s website at www.volcanocorp.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano’s business that are not historical facts may be considered “forward-looking statements,” including statements regarding the potential benefits of the products and procedures described above, results and implications of the data from the STLLR trial, FAME study, and PROSPECT study, commercial release and market adoption of the company’s technology, and the impact of clinical and other technical data. Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause Volcano’s results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company’s annual report on Form 10-K and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CONTACT: Edrienne Brandon of Volcano Corporation, +1-858-720-4136
Web site: http://www.volcanocorp.com/
